TB-500 is a synthetic peptide sold online for injury recovery, and the evidence behind that use comes from animal and cell studies, not from people. It is marketed as thymosin beta-4, a repair peptide the body makes, but a marketed TB-500 product analyzed in the lab was a short synthetic fragment of that peptide, its residues 17 to 23, while the natural peptide is a 43-amino-acid protein. Thymosin beta-4 speeds wound and heart-tissue healing and drives blood-vessel growth in rats, mice, and cell cultures, and as an eye drop it reduced dry-eye signs in two small human trials. None of that tests injected TB-500 for tendon, muscle, or joint recovery in people, which has no completed human trial.
TB-500 is not an approved drug, is sold as an unregulated research chemical of uncertain content, and is banned in sport by the World Anti-Doping Agency. This page explains what is studied and what is not. It is education, and it gives no dose.
Findings & Outcomes
What It Is
TB-500 is a peptide sold online, mostly as a powder for injection, and marketed for faster recovery from tendon, muscle, and joint injuries. The name it trades under is thymosin beta-4, written Tβ4, a peptide the body makes in most tissues. Thymosin beta-4 binds actin inside cells and takes part in cell migration, blood-vessel growth, and wound repair, which is the biology the marketing draws on.
The marketed product and the natural peptide are not the same molecule. When a TB-500 formulation was analyzed in a doping-control laboratory, its active ingredient was a short synthetic fragment: the stretch of thymosin beta-4 at residues 17 to 23, with an added acetyl group on one end. Natural thymosin beta-4 is a 43-amino-acid protein. The fragment covers the small region thought to carry the actin-binding and healing activity, so most human research on the whole protein does not directly test the grey-market fragment that people inject.
Anatomy
1The natural peptide
Thymosin beta-4 is a 43-amino-acid peptide the body produces in most tissues and in platelets. It binds the protein actin inside cells and takes part in cell movement, blood-vessel growth, and the repair of wounded tissue. This is the peptide that the healing research studied, almost all of it in animals and cell cultures.
2The marketed fragment
A TB-500 product analyzed in the laboratory was not the whole peptide. Its ingredient was a synthetic seven-amino-acid fragment, residues 17 to 23 of thymosin beta-4, with an acetyl group added to one end. That short piece covers the region thought to carry the actin-binding and healing activity, but it is a different molecule from the full protein.
3How it reaches people
TB-500 is sold as a research chemical, a label that sidesteps the approval a medicine needs. It ships as a lyophilized powder to be mixed and injected under the skin. Nothing checks its identity, dose, sterility, or purity before it goes into a syringe, and no approved medical use for injury recovery exists.
What It Does
The evidence for thymosin beta-4 is real, and it is preclinical. The healing and blood-vessel findings come from studies in rats, mice, and cultured cells, which show cause and effect in an animal or a dish but do not establish the same effect in a person. The one place the natural peptide reached human trials is the eye surface, where it was given as a drop, not injected for injury. Each finding below is graded at the strength of its own evidence, and none of it tests injected TB-500 for tendon, muscle, or joint recovery in people.
In animals, thymosin beta-4 speeds tissue repair. In a rat full-thickness wound model, the peptide increased the rate at which skin closed by about 42% at four days and as much as 61% at seven days over saline, with more wound contraction, more new collagen, and more blood-vessel growth. After a heart attack was induced in mice by tying off a coronary artery, the peptide improved the survival of heart-muscle cells and improved heart function, working through a signaling complex that switches on a cell-survival kinase. At the cell level, thymosin beta-4 acts as a chemoattractant that pulls human endothelial cells to migrate four to six times faster than medium alone and promotes the sprouting of new blood vessels, which is the mechanism proposed for its repair effects.
The human evidence is narrow. As an eye drop, thymosin beta-4 was tested in two small randomized trials for dry eye. In a 72-person trial it missed both of its primary endpoints, then showed improvements on some secondary measures, including a 27% reduction in ocular discomfort and less corneal staining. In a 9-person trial in severe dry eye it reduced ocular discomfort by about 35% and corneal staining by about 59% against placebo. This is human evidence for a topical eye treatment. It does not test the injected peptide, and it says nothing about recovery from a torn tendon or a strained muscle.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Thymosin beta-4 accelerated skin wound healing in rats
In rats, the natural peptide thymosin beta-4 made skin wounds close faster and grow more new tissue and blood vessels. TB-500 is sold on the strength of this kind of repair biology, but the healing was shown in animals, not in people.
Malinda and colleagues (1999) applied thymosin beta-4 topically or by injection into the abdomen in a rat full-thickness wound model and found reepithelialization increased about 42% at day 4 and as much as 61% at day 7 versus saline controls, with wounds contracting at least 11% more by day 7 and showing increased collagen deposition and angiogenesis. The peptide also stimulated keratinocyte migration in a Boyden chamber assay. The work is in rats, so it demonstrates the effect in an animal model and not in people, and it uses the whole peptide rather than the TB-500 fragment.
Who this may not transfer to:Shown in a rat wound model using the full thymosin beta-4 peptide; there is no completed human trial and no test of the marketed TB-500 fragment to transfer from.
Animal wound-healing data is a reason to study a compound, not evidence that injecting the TB-500 fragment repairs a tendon, muscle, or joint in a person.
The study · 1
Malinda et al., Thymosin beta4 accelerates wound healing · J Invest Dermatol 1999;113(3):364-368
Thymosin beta-4 drives endothelial cell migration and blood-vessel growth in cell and in vivo assays
In cell cultures, thymosin beta-4 pulls the cells that line blood vessels to move and multiply, which builds new blood vessels. This is the mechanism proposed for its healing effects, shown in a dish and in gel implants, not a health outcome in a person.
Malinda and colleagues (1997) reported that thymosin beta-4 acts as a chemoattractant for human umbilical vein endothelial cells, stimulating migration in Boyden chambers four- to sixfold over media alone, accelerating migration into a scratch-wounded monolayer, increasing matrix metalloproteinase production, and promoting cell migration in subcutaneously implanted Matrigel. This was the first direct evidence that the peptide promotes angiogenesis by moving endothelial cells. The work is cell-based and in vivo animal gel assays, so it characterizes a mechanism rather than a clinical benefit, and it does not test the marketed TB-500 fragment in people.
Who this may not transfer to:Shown in human endothelial cell cultures and animal gel implants; a mechanism, not a clinical result, and no human outcome trial exists.
A mechanism in cell culture explains why the peptide could aid repair, but a moved cell in a dish is not a healed injury in a person.
The study · 1
Malinda et al., Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells · FASEB J 1997;11(6):474-481
Thymosin beta-4 eye drops improved some dry-eye signs and symptoms in two small human trials
The one place the natural peptide reached human trials is the eye. As an eye drop it eased some dry-eye signs in two small studies, though the larger one missed its main goals. This is human evidence for a topical eye treatment, not for injecting TB-500 to heal an injury.
Sosne and Ousler (2015) randomized 72 subjects with moderate to severe dry eye to 0.1% thymosin beta-4 (RGN-259) or placebo for 28 days using a controlled adverse environment model; neither primary endpoint reached significance, but secondary measures improved, including a 27% reduction in ocular discomfort on day 28 (P=0.0244) and reduced central and superior corneal staining, with no adverse events. Sosne, Dunn and Kim (2015) treated 9 patients with severe dry eye in a randomized, double-masked, placebo-controlled phase 2 trial, reporting a 35.1% reduction in ocular discomfort (P=0.0141) and a 59.1% reduction in total corneal fluorescein staining (P=0.0108) at day 56. Both are small topical eye-drop studies of the whole peptide; neither tests the injected TB-500 fragment or any musculoskeletal recovery outcome.
Who this may not transfer to:Studied as a topical eye drop in adults with dry eye; the effect is specific to the ocular surface and the whole peptide, and does not transfer to injected TB-500 for injury.
This is the strongest human evidence for thymosin beta-4, and it is for an eye drop. It does not establish that injecting TB-500 helps a tendon, muscle, or joint.
The studies · 2
Sosne and Ousler, Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial (CAE model) · Clin Ophthalmol 2015;9:877-884
Sosne et al., Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial · Cornea 2015;34(5):491-496
A marketed TB-500 product was a short synthetic fragment of thymosin beta-4, not the whole peptide
When a TB-500 product was analyzed in the lab, its ingredient was a short synthetic piece of thymosin beta-4, the stretch at residues 17 to 23, not the whole peptide. So the animal and human research on the full protein does not directly test the fragment that people inject.
Esposito and colleagues (2012) detected and identified the N-terminal acetylated 17-23 fragment of human thymosin beta-4 (Ac-LKKTETQ) as the ingredient in the formulation TB-500 using high-resolution mass spectrometry, then synthesized the fragment and developed a detection strategy for plasma and urine. A doping-control method paper (Ho and colleagues, 2012) likewise describes the key ingredient of TB-500 as the acetylated peptide LKKTETQ, the residue 17-23 active site of thymosin beta-4. The marketed product is therefore a short synthetic fragment, which is a different molecule from the full peptide most healing research studied.
Who this may not transfer to:An analytical chemistry finding about what a marketed product contains, not a human or animal outcome.
Read claims about TB-500 with the substitution in mind: research on the whole peptide is being used to sell a small fragment of it.
The study · 1
Esposito et al., Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500 · Drug Test Anal 2012;4(9):733-738
Heart And Vascular
Thymosin beta-4 improved heart-cell survival and cardiac function after induced heart attack in mice
After an induced heart attack in mice, thymosin beta-4 helped heart-muscle cells survive and improved how the heart pumped. This is animal evidence about the natural peptide, not a test of injected TB-500 in people.
Bock-Marquette and colleagues (2004) showed that thymosin beta-4 promotes migration and survival of embryonic and postnatal cardiomyocytes and forms a complex with PINCH and integrin-linked kinase that activates Akt. After coronary artery ligation in mice, treatment upregulated integrin-linked kinase and Akt activity in the heart, enhanced early myocyte survival, and improved cardiac function. The findings are in a mouse model of acute myocardial damage and describe the full peptide, so they do not establish a cardiac or recovery benefit of the injected TB-500 fragment in humans.
Who this may not transfer to:Shown in a mouse model of acute heart injury using the full thymosin beta-4 peptide; no human trial exists to transfer from.
This mouse cardiac-repair result explains the healing mechanism the marketing invokes, but it is preclinical and does not support injecting TB-500 for injury or heart health in people.
The study · 1
Bock-Marquette et al., Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair · Nature 2004;432(7016):466-472
How It Works
Thymosin beta-4 is the most abundant actin-binding peptide inside cells. Actin is the protein that gives a cell its shape and lets it crawl, and by holding a pool of unassembled actin ready, thymosin beta-4 takes part in how cells migrate into a wound. The peptide also draws endothelial cells, the cells that line blood vessels, to move and form new vessels, a process called angiogenesis, and it dampens some inflammatory signaling. Faster cell migration, more new blood vessels, and less inflammation are the steps of ordinary tissue repair, which is why the peptide speeds healing in animal wounds and why it is marketed for injury.
The short fragment sold as TB-500 is built from the region of the peptide, residues 17 to 23, that carries the actin-binding sequence. Whether a seven-amino-acid fragment reproduces the full peptide's activity in a living person is not established. Peptides are digested in the gut, so the product is injected rather than swallowed, and that is where the sourcing and sterility risks arise.
Injecting a research chemical means putting an unverified substance at an unknown dose into your body, and that risk stands apart from whether the peptide does anything at all.
How to Think About It
How to Think About It
This section is education, not a protocol, and it gives no dose. It offers a way to place TB-500 against the evidence and to see why the marketed use sits ahead of what has been shown in people.
The healing research is on thymosin beta-4, the full 43-amino-acid protein, done mostly in rats, mice, and cell cultures. The product injected as TB-500 is a short synthetic fragment of that protein. Evidence about the whole peptide in an animal does not automatically carry to a seven-amino-acid fragment in a person.
No completed randomized human trial tests TB-500, or thymosin beta-4 by injection, for tendon, muscle, or joint recovery. The animal healing data is a reason to study a compound, not evidence that it works in people. The human trials that exist are for an eye drop, a different route and a different problem.
TB-500 is not an approved drug. It is sold as a research chemical of uncertain content, and it is on the World Anti-Doping Agency prohibited list, so an athlete who uses it can fail a drug test. Anti-doping laboratories have built methods to detect it in urine and blood.
A doctor or a physical therapist can tell you what the evidence supports for the injury you are trying to heal, and can check whether the problem needs imaging or a different treatment. That conversation is the practice here, in place of injecting an unregulated substance on the strength of animal studies.
Go Deeper
- BPC-157: the other healing peptide sold the same way, with the same shape of evidence, a body of rodent research and no completed human trial.
- Peptides: how the approved peptide drugs, like the GLP-1 medicines, differ from the fitness and anti-aging peptides sold online, and why the two share little beyond the word.
- Protein and muscle: the daily protein that feeds muscle repair, a plainer and better-tested lever than any injected peptide.
- Resistance training: the loading that builds tendon and bone strength over months, and the training side of recovering from injury.
- Copper peptides (GHK-Cu): another peptide sold for repair, this one topical and aimed at skin and hair, with the same gap between marketing and trial evidence.
The Chinese Medicine View
Thymosin beta-4 is a product of modern biochemistry, isolated in the last century, so there is no classical Chinese entry for it. No historical text assigns it a channel, a temperature, or a flavor, and no traditional formula contains it. What follows places the marketed use against the tradition as a lens, and it borrows no classical claim, because none exists.
The tradition does reason about the territory the peptide is sold for, which is healing wounds and knitting damaged sinew. Chinese medicine reads recovery from injury through the movement of Qi and Blood: a bruise or a strain is understood as Blood that has stopped moving and pooled, and treatment aims to move Blood, disperse the stasis, and then nourish what was torn so it can rebuild. Herbs and formulas in the trauma tradition, and the external medicine that grew up around bonesetting, are directed at that sequence. Read as a map this rhymes with the modern account of cell migration and new blood vessels entering a wound, but the two are separate languages and neither translates into the other.
The tradition also carries a caution that fits this case. Forcing a system to do more than its constitution allows is understood to draw down reserve rather than build it, and repair is held to depend on the strength a person already has to spend. Nothing in that framework endorses injecting an isolated substance to drive healing faster, and the classical instruction in an injury is to support the body's own capacity to move Blood and mend, not to override it.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Illegally sold injectable peptides analyzed in the lab have shown identity and quality problems
Janvier and colleagues (2017) developed and validated a chromatography-mass spectrometry method to identify and quantify the illegal peptides most often encountered on the European market, noting that these lyophilized peptides under 5 kDa are meant for subcutaneous injection and are easily bought online. Analyses in this literature have repeatedly found falsified injectable peptide products with incorrect identity, wrong or missing active ingredient, and impurities. TB-500 is sold in exactly this grey market, so the composition, dose, sterility, and purity of a given product are not assured.Janvier et al., Analysis of illegal peptide drugs via HILIC-DAD-MS
TB-500 is treated as a doping agent and can be detected by anti-doping laboratories
Ho and colleagues (2012) developed a method to detect the acetylated LKKTETQ ingredient of TB-500 and its metabolites in urine and plasma, confirming it at 0.02 ng/mL in plasma and 0.01 ng/mL in urine after a single 10 mg dose, as part of controlling misuse of the peptide in sport. Thymosin beta-4 and its synthetic fragments fall under the World Anti-Doping Agency prohibited list, and the detection work reflects that TB-500 is treated as a doping agent rather than an approved therapy.Ho et al., Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta 4, in equine urine and plasma
It is an unregulated research chemical of uncertain content
TB-500 is made and sold outside pharmaceutical controls, labeled for research use. A marketed product analyzed in the laboratory was a short synthetic fragment rather than the whole peptide, and analyses of illegally sold injectable peptides have found wrong doses, missing ingredient, and impurities. What is in a given vial is unknown before it goes into the syringe.
Injecting a grey-market product carries its own risks
Beyond whether the peptide does anything, self-injecting a non-sterile or mislabeled product can cause infection, abscess, and injection-site reactions, at a dose no one has verified. No human trial has tested TB-500 for safe self-administration, and the dosing that circulates comes from forums, not from research.
Long-term human safety is unknown
There is no completed human trial of injected TB-500 or thymosin beta-4 for injury, so its safety in people over weeks, months, or years is not established. The peptide promotes blood-vessel growth and cell migration, and because those are also processes a tumor uses, driving them with an unstudied injected compound is an open concern that no trial has resolved.
It is not an approved drug and is banned in sport
No regulator has judged TB-500 safe or effective for the recovery uses it is sold for, and no manufacturer is accountable for what a batch contains. Thymosin beta-4 and its fragments are on the World Anti-Doping Agency prohibited list, and anti-doping laboratories test for them, so an athlete subject to testing who uses it risks a sanction.
See a clinician before acting on animal data
For an injury you are trying to heal, a doctor or physical therapist can tell you what actually helps and whether the problem needs imaging. An injury that is not improving, a joint that locks or gives way, or pain that wakes you at night deserves a professional look rather than an injected research peptide.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Is TB-500 the same as thymosin beta-4?
Not exactly. Thymosin beta-4 is a 43-amino-acid peptide the body makes. When a TB-500 product was analyzed in the laboratory, its ingredient was a short synthetic fragment of that peptide, the stretch at residues 17 to 23 with an added acetyl group, which covers the small region thought to carry the healing activity. So the marketing borrows the name and the biology of the whole peptide for a product that is a fragment of it.
Does TB-500 heal injuries in people?
There is no completed human trial showing that it does. The healing evidence for thymosin beta-4 comes from rats, mice, and cell cultures, where the peptide speeds wound closure and grows new blood vessels. That work is a reason to study the compound. It is not evidence that injecting the TB-500 fragment repairs a tendon, muscle, or joint in a person, and buying it online adds the separate risks of unknown purity and dose.
Is there any human evidence for thymosin beta-4 at all?
Yes, for the eye surface. As an eye drop, thymosin beta-4 was tested in two small randomized dry-eye trials. The larger one, with 72 people, missed both of its main endpoints and then improved some secondary measures; a 9-person trial in severe dry eye reduced discomfort and corneal damage against placebo. This is human evidence for a topical treatment of the eye, a different route and a different condition from injecting the peptide for injury.
Is TB-500 legal, and is it allowed in sport?
It occupies a grey area. It is sold labeled for research use, which sidesteps the approval a medicine needs, and it is not an approved drug for any human use. In sport it is not allowed: thymosin beta-4 and its fragments are on the World Anti-Doping Agency prohibited list, and testing laboratories have developed methods to detect it, so an athlete who uses it can fail a drug test.
Why is injecting it a risk even if the peptide is harmless?
Because you cannot be sure what is in the vial or how much. Products sold this way are made outside pharmaceutical controls, and chemical analyses of illegally sold peptides have found wrong doses, missing active ingredient, and contamination. Self-injecting a non-sterile or mislabeled product can cause infection and injection-site harm on its own, before the question of whether the peptide does anything is even reached.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 8 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.